New Antibiotic Hits the Market to Tackle Stubborn UTIs

  • 📰 Gizmodo
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 51%

Business News News

Business Business Latest News,Business Business Headlines

The Food and Drug Administration has approved Iterum Therapeutics' Orlynvah, the first drug of its kind, which is designed to treat certain UTIs resistant to other drugs.

No doubt about it, UTIs suck. They burn, they itch, they come back just when you think you’re in the clear. But for those dealing with these relentless infections, there’s finally a new line of defense.

Orlynvah is the first drug of its kind. It contains a combination of sulopenem etzadroxil, which belongs to a subclass of antibacterials called penems, and probenecid, a renal tubular transport inhibitor that has been used in the past to boost the duration of antibiotics in our body. Penems arethat has shown great promise in treating a wide variety of commonly resistant germs, but Orlynvah is the first ever oral penem to be approved in the U.S.bacteria.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 556. in BUSİNESS

Business Business Latest News, Business Business Headlines